Core Viewpoint - The supervisory board of Guangdong Shengyi Technology Co., Ltd. has reviewed and approved the repurchase and cancellation of certain restricted stocks that have been granted but not yet released from restrictions, in accordance with relevant laws and regulations [1] Group 1: Compliance and Approval - The supervisory board believes that the company's action to repurchase and cancel part of the restricted stocks aligns with the relevant laws, regulations, and the draft of the 2024 Restricted Stock Incentive Plan [1] - The board confirms that this action does not harm the interests of shareholders [1]

证券代码：301577 证券简称：美信科技 公告编号：2025-040 广东美信科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 广东美信科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日召开 了第四届董事会第一次会议，公司董事会决定于 2025 年 9 月 3 日以现场表决与 网络投票相结合的方式召开公司 2025 年第二次临时股东会（以下简称"本次会 议"或"本次股东会"）。现将会议的有关情况通知如下： 一、召开会议的基本情况 会第一次会议，审议通过了《关于提请召开 2025 年第二次临时股东会的议案》， 本次股东会的召集、召开符合相关法律、行政法规、部门规章、规范性文件、深 圳证券交易所规则和《公司章程》等有关规定。 （1）现场会议召开时间为：2025 年 9 月 3 日（星期三）下午 15:00。 （2）网络投票时间为：通过深圳证券交易所（以下简称"深交所"）交易 系统进行网络投票的具体时间为：2025 年 9 月 3 日上午 9:15-9：25，9：30-11:30， 下午 ...

证券代码：688737 证券简称：中自科技 公告编号：2025-047 中自科技股份有限公司董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划授予激励对象名单 的公示情况说明及核查意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 中自科技股份有限公司（以下简称"公司"）于 2025 年 8 月 6 日召开了第四届董 事会第六次临时会议及第四届监事会第六次临时会议，审议通过了《关于 <公司 ensp="ensp"> 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。 根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025 年限制性 股票激励计划授予激励对象名单在公司内部进行了公示。 公司董事会薪酬与考核委 员会（以下简称"薪酬与考核委员会"）结合公示情况对拟授予激励对象进行了核查， 相关公示情况及核查情况如下： 一、公示情况及核查方式 公司于 2025 年 8 月 7 日在上海证券交易所网站（www.sse.com.cn）上披露了《中 自科技股份有限公司 2025 ...

Core Viewpoint - The announcement details the public disclosure and verification of the list of incentive recipients for the 2025 restricted stock incentive plan of Zhongzi Technology Co., Ltd. [1] Disclosure and Verification - The company held a board meeting on August 6, 2025, to approve the draft of the 2025 restricted stock incentive plan and related proposals [1] - The list of incentive recipients was publicly disclosed on the Shanghai Stock Exchange website on August 7, 2025, and an internal public notice was conducted from August 6 to August 15, 2025 [1] - During the public notice period, employees were allowed to provide feedback to the supervisory board, but no objections were received [2] Supervisory Board's Verification Opinion - The supervisory board verified the eligibility of the proposed incentive recipients against various criteria, including any disqualifications from the past 12 months [2] - The verification confirmed that all individuals listed as incentive recipients meet the conditions set forth in relevant laws, regulations, and the incentive plan [2]

Core Viewpoint - The company has confirmed the eligibility of the participants in the 2025 restricted stock incentive plan, ensuring compliance with relevant laws and regulations [1][2]. Summary by Sections Eligibility of Participants - The participants in the 2025 restricted stock incentive plan meet the qualifications set forth by the Company Law, Securities Law, and relevant regulations [1]. - The incentive plan includes directors, senior management, middle management, core technical personnel, and other employees deemed necessary for motivation, excluding independent directors and shareholders holding more than 5% of the company [1]. Compliance with Regulations - All participants do not fall under the disqualifications outlined in Article 8 of the Management Measures, including recent inappropriate designations by the stock exchange or the China Securities Regulatory Commission (CSRC) [2]. - The basic information of the participants is accurate, with no instances of falsehood or significant misrepresentation [2]. Conclusion - The board's compensation and assessment committee concludes that the selected individuals for the 2025 restricted stock incentive plan are legally and effectively qualified as per the company's regulations and the draft plan [2].

Group 1 - The company has conducted a self-examination regarding the trading activities of insiders and initial grant recipients related to the 2025 Restricted Stock Incentive Plan, confirming no insider trading occurred during the specified period [1][2]. - The self-examination covered the period of six months prior to the public disclosure of the incentive plan, and it was found that 22 incentive recipients traded the company's stock without knowledge of the specific details of the plan [2]. - The company has established strict information disclosure and insider information management systems, ensuring that only a limited number of personnel were involved in the planning and discussion of the incentive plan [2][3]. Group 2 - The company has taken necessary confidentiality measures and registered insider information recipients as per the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [1][2]. - The conclusion of the self-examination indicates that there were no instances of insider trading or leakage of insider information related to the incentive plan prior to its public announcement [2].

Core Viewpoint - The supervisory board of Shanghai Kasei Biotechnology Co., Ltd. held a meeting to review and approve the company's 2025 semi-annual report and related proposals, ensuring compliance with legal and regulatory requirements [1][2][3][4][5] Group 1: Supervisory Board Meeting - The meeting was convened on August 15, 2025, with all three members present, confirming the legality and validity of the resolutions made [1] - The supervisory board confirmed that the 2025 semi-annual report and its summary were prepared in accordance with relevant laws and internal regulations, ensuring the information disclosed is true, accurate, and complete [1][2] Group 2: Fund Management and Usage - The board approved the special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with regulatory requirements and proper management of the funds [2][3] - The company ensured that the raised funds were stored in dedicated accounts and used for specified purposes, with no violations reported [2] Group 3: Stock Incentive Plans - The board approved the cancellation of unvested restricted stock from the 2020 incentive plan, confirming that the action complies with relevant laws and does not harm the interests of the company or its shareholders [3][4] - The board also approved an adjustment to the grant price of the 2022 restricted stock incentive plan from 56.45 yuan per share to 56.05 yuan per share, ensuring the adjustment followed legal procedures [4][5] - Additionally, the board approved the cancellation of unvested restricted stock from the 2022 incentive plan, affirming compliance with applicable regulations [5]

Core Viewpoint - The company has announced the cancellation of certain unvested restricted stock from the 2020 incentive plan due to unmet performance criteria, which will not significantly impact its financial status or operational stability [1][8]. Group 1: Announcement Details - The board of directors has approved the proposal to cancel unvested restricted stock from the 2020 incentive plan [1][6]. - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the incentive plan [1][2]. - The independent directors have provided their opinions on the related proposals [2][4]. Group 2: Performance Criteria - The performance targets for the fourth vesting period and the third reserved grant period required a revenue growth rate of at least 186% and a net profit growth rate of at least 186% for full vesting [6][7]. - The company's 2024 revenue was reported at 2,957.91 million, reflecting a 97.56% increase compared to 2020, while the net profit was 483.89 million, showing a 5.62% increase [7]. Group 3: Impact of Cancellation - The cancellation of the unvested restricted stock will not have a significant impact on the company's financial condition or operational performance [8]. - The cancellation marks the conclusion of the 2020 restricted stock incentive plan [8]. Group 4: Compliance and Legal Opinions - The cancellation of the unvested restricted stock complies with relevant laws and regulations, ensuring no harm to the company or shareholders [8]. - Legal opinions confirm that the necessary authorizations and approvals for the cancellation have been obtained [8].

Core Viewpoint - The company has announced adjustments to the grant price of its 2022 restricted stock incentive plan and the cancellation of certain unvested restricted stocks, following the completion of its annual profit distribution plan [1][5][8]. Summary by Sections Decision Process and Disclosure - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the 2022 restricted stock incentive plan, including independent opinions from the board of directors [1][2][3]. Adjustments and Results - The grant price for the 2022 restricted stock incentive plan has been adjusted from 56.45 yuan per share to 56.05 yuan per share due to the implementation of a cash dividend distribution of 4.00 yuan per 10 shares [5][6][8]. - The adjustment is in accordance with the regulations outlined in the "Management Measures for Equity Incentives of Listed Companies" and the 2022 incentive plan [5][8]. Cancellation of Restricted Stocks - A total of 69.881 million shares of unvested restricted stocks will be canceled due to the company not meeting the performance conditions required for vesting [7][8]. - The performance conditions included a minimum revenue growth rate of 186% for the first vesting period and 107% for the second vesting period, which were not achieved [6][7]. Impact on the Company - The adjustments to the grant price and the cancellation of unvested restricted stocks are not expected to have a significant impact on the company's financial status or operational stability [8]. Supervisory Board Opinion - The supervisory board has agreed that the adjustments to the grant price and the cancellation of unvested stocks comply with relevant laws and regulations, and do not harm the interests of the company or its shareholders [8][9].

Core Viewpoint - The legal opinion issued by Shanghai Jintiancheng Law Firm confirms that the cancellation of certain unvested restricted stock awards under the 2020 incentive plan of Shanghai Kaisa Biotechnology Co., Ltd. has obtained the necessary authorizations and approvals, complying with relevant regulations [1][7][8]. Group 1: Authorization and Approval - The legal opinion is based on the compliance with the Securities Law, Company Law, and relevant regulations regarding the incentive plan [1][2]. - The company has held multiple meetings to review and approve the necessary resolutions related to the incentive plan and the cancellation of unvested stocks [3][4][5][6]. Group 2: Cancellation of Restricted Stocks - The company is required to cancel 97,650 shares of the first grant's fourth vesting period and 38,780 shares of the reserved grant's third vesting period due to unmet performance conditions [8]. - The total number of restricted stocks to be canceled amounts to 136,430 shares, which does not require further shareholder approval as per the board's authorization [8][7]. Group 3: Performance Conditions - The performance targets for the fourth vesting period and the third reserved grant period were not met, with required revenue growth rates of 186% and 107% respectively [8]. - The company's 2024 revenue was reported at 2,957.91 million yuan, a 97.56% increase from 2020, while the net profit was 483.89 million yuan, a 5.62% increase from 2020, indicating that the performance conditions were not satisfied [8].